2001
DOI: 10.1017/s0266462301106124
|View full text |Cite
|
Sign up to set email alerts
|

Health Policy, Health Technology Assessment, and Screening in Europe

Abstract: The major conclusion is that countries of Europe need to develop HTA as part of prevention policies.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2003
2003
2006
2006

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 2 publications
0
1
0
1
Order By: Relevance
“…However, high tech options for diagnosis are expanding at a faster pace than diagnostic and implementation research can keep up with, and the gap between the offer of technological procedures and the evidence of their usefulness is likely to progressively widen in the future. This argues for the urgent need of a health technology assessment agency to review and give advice about the efficient use of present and future biomedical technology at both a national and European level (Banta, 2001 …”
Section: Discussionmentioning
confidence: 99%
“…However, high tech options for diagnosis are expanding at a faster pace than diagnostic and implementation research can keep up with, and the gap between the offer of technological procedures and the evidence of their usefulness is likely to progressively widen in the future. This argues for the urgent need of a health technology assessment agency to review and give advice about the efficient use of present and future biomedical technology at both a national and European level (Banta, 2001 …”
Section: Discussionmentioning
confidence: 99%
“…La mamografía de cribado se considera el procedimiento más efectivo para la detección precoz del cáncer de mama y la disminución de la mortalidad por la enfermedad. La evidencia científica disponible muestra que la mamografía de cribado en mujeres de 50 a 64 años puede reducir al menos un 20% la mortalidad por cáncer de mama 3,4 , si bien la efectividad de la prueba depende en gran medida de la edad de la mujer. La mamografía puede beneficiar a las mujeres de 40 a 50 años de edad, aunque fundamentalmente está indicada en las mayores de 50 años de edad 5 .…”
Section: Introductionunclassified